Detection and visualization of neoplastic tissues and other tissues
First Claim
1. A method for in vivo labeling of selected tissues, comprising:
- contacting the tissue with a conjugate comprising a first component of a bioluminescence generating system, wherein the first component is a luciferin or luciferase; and
then contacting the tissue with the remaining components of the system, wherein;
contacting is effected in vivo.
1 Assignment
0 Petitions
Accused Products
Abstract
Kits containing the diagnostic systems and diagnostic systems that rely on bioluminescence for visualizing tissues in situ are provided. The systems include compositions containing conjugates that include a tissue specific, particularly a tumor-specific, targeting agent linked to a targeted agent, a luciferase or luciferin. The systems also include a second composition that contains the remaining components of a bioluminescence generating reaction. Administration of the compositions results production of light by targeted tissues that permits the detection and localization of neoplastic tissue for surgical removal.
-
Citations
27 Claims
-
1. A method for in vivo labeling of selected tissues, comprising:
-
contacting the tissue with a conjugate comprising a first component of a bioluminescence generating system, wherein the first component is a luciferin or luciferase; and
then contacting the tissue with the remaining components of the system, wherein;
contacting is effected in vivo. - View Dependent Claims (2, 3, 15)
-
-
4. A method for in vivo or in situ labeling or visualizing selected tissues, comprising:
-
(a) administering a first composition comprising, in a pharmaceutically acceptable vehicle, a conjugate that comprises a targeted agent that is a component of the bioluminescence generating system, and a targeting agent, wherein the conjugate binds to a cell surface receptor, the targeted agent is a luciferase or luciferin, the targeting agent specifically binds to a cell surface protein; and
(b) administering a second composition, comprising, in a pharmaceutically acceptable vehicle, another component of the bioluminescence generating system, wherein;
the bioluminescence generating system comprises a luciferase and a luciferin;
the first composition and second composition are administered simultaneously, or successively. - View Dependent Claims (5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)
-
Specification